Katharina Maisel, Ph.D.
University of Maryland-College Park
Immunity in LAM: Assessing the Role of Lymphatic Immunomodulation and Potential for Adjuvant Based Therapies
Pulmonary lymphangioleiomyomatosis (LAM) is a devastating progressive disease primarily affecting women of childbearing age. In LAM patients, abnormal muscle-like cells begin to grow out of control in certain organs or tissues, especially the lungs, lymph nodes, and kidneys. Two hallmarks of LAM are expanded lymphatic vessels and an immunosuppressive microenvironment in the lungs. We will determine the effects of LAM cells on lymphatic functions, and therapeutic efficacy of immunotherapies used in combination with rapamycin, the only FDA-approved LAM treatment. This work will bring novel insights into effects of LAM on lymphatic functions and may provide new avenues for LAM treatments.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.